Probiotics Cut Depression and Anxiety Symptoms in Older Adults, Pilot Trial Finds

Late-life depression is more common than most people realize, and it responds less reliably to standard antidepressants than depression in younger adults. A new pilot trial published in the Journal of the American Geriatrics Society suggests that adding a daily probiotic to standard care may offer a modest but meaningful extra lift, reducing both depressive and anxiety symptoms in adults aged 60 and older with moderate depression.

Probiotic therapy modestly reduced depressive and anxiety symptoms

The trial enrolled 58 participants from India, all aged 60 or older with moderate depression, and randomized them 1:1 to receive either a daily probiotic supplement or a placebo for 12 weeks, while everyone continued their prescribed antidepressant regimen. Participants were then followed for an additional 12 weeks, making the total study window 24 weeks. Researchers measured outcomes using validated psychological scales, including the MADRS for depression severity and the GAD-7 for anxiety, alongside serum levels of brain-derived neurotrophic factor (BDNF), a protein important for nerve cell health, and fecal microbiota profiling.

Both groups improved substantially over the course of the study, which the researchers attribute primarily to the standard antidepressant care everyone received. But the probiotic group showed additional, statistically meaningful reductions in depressive and anxiety symptoms beyond what the placebo group experienced. Quality of life scores, however, did not differ clearly between the two groups.

Why late-life depression is a pressing and underserved problem

Depression affects roughly 10 to 20 percent of older adults globally, according to a systematic review and meta-analysis drawing on WHO estimates, yet it is frequently undertreated or misattributed to the normal effects of aging. The CDC emphasizes that depression is not a normal part of getting older and is a treatable medical condition, but stigma and overlapping physical symptoms often delay diagnosis. Standard antidepressants work for many older patients, though side-effect profiles and polypharmacy risks make clinicians cautious. An adjunct intervention that is relatively safe, affordable, and biologically grounded has obvious appeal.

How the gut-brain axis connects microbiome changes to mood

The biological rationale behind the trial rests on the gut-brain axis, a bidirectional communication network linking the gastrointestinal tract to the central nervous system through neural, endocrine, and immune pathways. The vagus nerve is the primary physical conduit, but gut bacteria also synthesize neuroactive compounds directly: serotonin, dopamine, and GABA are all produced in part by microbial activity in the intestine. Aging progressively disrupts gut bacteria composition, which may in turn promote neuroinflammation, reduce neurotransmitter output, and heighten stress reactivity. The researchers tracked BDNF levels as one indicator of whether probiotics were influencing nerve cell health through this pathway, though the article does not report specific BDNF values for each group.

Limitations that matter before reading too much into the results

This was an openly labeled pilot trial, meaning it was designed to test feasibility and signal, not to deliver definitive answers. Fifty-eight participants is a small sample, and the study drew exclusively from one site in India, which limits how broadly the findings can be generalized to other populations or healthcare contexts. Researchers were measuring multiple outcomes simultaneously, raising the usual caution about which improvements were primary and which were secondary. Broader reviews of probiotic research in psychiatry have flagged small sample sizes, inconsistent biomarker collection, and the absence of large-scale replication as recurring problems across the field, and this trial, by the authors' own admission, is no exception.

The quality-of-life finding is also worth noting. Despite real reductions in depression and anxiety scores, participants taking probiotics did not report clearly better overall quality of life compared to those taking a placebo. That gap between symptom scores and lived experience is common in clinical research, but it is a reminder that statistical significance on a rating scale does not always translate into outcomes patients notice day to day.

A larger trial is already in planning, according to lead researcher

Dr. Saibal Das, the study's lead researcher, described the results as encouraging enough to justify a larger follow-up. "The results of our study are novel, and we are now planning a follow-up, larger-scale clinical trial due to the encouraging findings," he said. He has also framed the broader goal as developing affordable healthcare solutions that can reach wider populations, which fits the profile of a probiotic intervention: relatively low cost, widely available, and carrying a safety record that makes it easier to justify as an add-on rather than a replacement for existing care.

For now, the findings support probiotics as a biologically plausible and apparently safe adjunct to antidepressant treatment in older adults. What the field still needs is the larger, more diverse trial that Dr. Das is planning, one capable of identifying which patients benefit most, which probiotic strains or formulations matter, and whether the gut microbiome changes observed here replicate consistently across different populations and clinical settings.

Evidence rating

EMERGING — 73/100

Caveats:

• Pilot trial with only 58 participants — underpowered to detect small effects reliably.
• Both groups improved substantially on antidepressants; the probiotic advantage was modest and did not extend to quality of life.
• Conducted in a single country (India); findings may not generalize to other populations.
• The specific probiotic strains used are not named in available reporting, making replication or product selection difficult.
• Funding source was not disclosed; independent replication has not yet occurred.
• Larger trials are needed before clinical recommendations can be made.

Pilot double-blind RCT (n=58) testing daily probiotics as an adjunct to antidepressants in adults aged 60 and older over 24 weeks. The study shows modest symptomatic benefit but cannot establish definitive causation at this sample size, and specific probiotic strains were not clearly reported in available summaries. Findings are consistent with prior gut-brain axis research but have not yet been independently replicated.

References

1. (2026). Research Links Probiotics to Improved Mental Health in Older Adults with Depression. https://news.ssbcrack.com/research-links-probiotics-to-improved-mental-health-in-older-adults-with-depression/
2. Preeti Sinha, Prasun Chatterjee, Preethy Kathiresan, et al. (2026). Efficacy of Adjunct PRObiotics as Compared to the Standard Care in Moderate Unipolar Depression Among Geriatric Patients: A Randomized Double‐Blind Placebo‐Controlled Pilot Multi‐Center Trial ( PRODG ). Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.70530
3. Yosef Zenebe, Baye Akele, Mulugeta W/Selassie, Mogesie Necho (2021). Prevalence and determinants of depression among old age: a systematic review and meta-analysis. Annals of General Psychiatry. https://doi.org/10.1186/s12991-021-00375-x
4. Depression and Aging | Healthy Aging – CDC. cdc.gov. https://www.cdc.gov/aging/mentalhealth/depression.htm
5. Zhangcheng Zhu, Yiwen Cheng, Xia Liu, et al. (2025). The microbiota-gut-brain axis in depression: unraveling the relationships and therapeutic opportunities. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1644160
6. Evan Forth, Benjamin Buehner, Ana Storer, Cassandra Sgarbossa, Roumen Milev, Arthi Chinna Meyyappan (2023). Systematic review of probiotics as an adjuvant treatment for psychiatric disorders. Frontiers in Behavioral Neuroscience. https://doi.org/10.3389/fnbeh.2023.1111349